News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,143 Results
Type
Article (52527)
Company Profile (197)
Press Release (645419)
Section
Business (199949)
Career Advice (3365)
Deals (35550)
Drug Delivery (122)
Drug Development (79164)
Employer Resources (188)
FDA (16090)
Job Trends (15358)
News (340435)
Policy (34090)
Tag
2024 BioCapital Digital (2)
2024 BioForest Digital (11)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (3)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (14)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (6)
2024 Genetown Digital (2)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (5)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (2)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2873)
Accelerated approval (5)
Adcomms (28)
Allergies (84)
Alliances (48476)
ALS (91)
Alzheimer's disease (1427)
Antibody-drug conjugate (ADC) (132)
Approvals (16055)
Artificial intelligence (260)
Autoimmune disease (22)
Automation (12)
Bankruptcy (351)
Best Places to Work (12199)
BIOSECURE Act (21)
Biosimilars (112)
Biotechnology (126)
Bladder cancer (63)
Brain cancer (29)
Breast cancer (267)
Cancer (2123)
Cardiovascular disease (186)
Career advice (2831)
Career pathing (33)
CAR-T (152)
Cell therapy (428)
Cervical cancer (20)
Clinical research (63950)
Collaboration (807)
Compensation (420)
Complete response letters (29)
COVID-19 (2815)
CRISPR (42)
C-suite (230)
Cystic fibrosis (103)
Data (2022)
Decentralized trials (2)
Denatured (32)
Depression (49)
Diabetes (269)
Diagnostics (6662)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (121)
Drug pricing (120)
Drug shortages (32)
Duchenne muscular dystrophy (91)
Earnings (80583)
Editorial (39)
Employer branding (24)
Employer resources (160)
Events (108183)
Executive appointments (684)
FDA (17240)
Featured Employer (45)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (734)
Gene editing (109)
Generative AI (23)
Gene therapy (313)
GLP-1 (805)
Government (4858)
Grass and pollen (5)
Guidances (49)
Healthcare (20161)
Huntington's disease (23)
IgA nephropathy (28)
Immunology and inflammation (128)
Indications (27)
Infectious disease (2962)
Inflammatory bowel disease (143)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (89)
Interviews (647)
IPO (17000)
IRA (50)
Job creations (3596)
Job search strategy (2317)
Kidney cancer (10)
Labor market (36)
Layoffs (507)
Leadership (20)
Legal (8508)
Liver cancer (73)
Lung cancer (310)
Lymphoma (138)
Machine learning (4)
Management (63)
Manufacturing (296)
MASH (67)
Medical device (13821)
Medtech (13826)
Mergers & acquisitions (19067)
Metabolic disorders (715)
Multiple sclerosis (76)
NASH (23)
Neurodegenerative disease (101)
Neuropsychiatric disorders (31)
Neuroscience (1961)
NextGen: Class of 2025 (7124)
Non-profit (4898)
Northern California (2435)
Now hiring (36)
Obesity (390)
Opinion (266)
Ovarian cancer (74)
Pain (85)
Pancreatic cancer (77)
Parkinson's disease (146)
Partnered (20)
Patents (212)
Patient recruitment (98)
Peanut (49)
People (58342)
Pharmaceutical (55)
Pharmacy benefit managers (20)
Phase I (19734)
Phase II (28225)
Phase III (21475)
Pipeline (1101)
Podcasts (97)
Policy (139)
Postmarket research (2403)
Preclinical (8236)
Press Release (69)
Prostate cancer (97)
Psychedelics (38)
Radiopharmaceuticals (260)
Rare diseases (399)
Real estate (6021)
Recruiting (73)
Regulatory (22831)
Reports (44)
Research institute (2534)
Resumes & cover letters (555)
Rett syndrome (4)
RNA editing (4)
RSV (47)
Schizophrenia (75)
Series A (132)
Series B (84)
Service/supplier (19)
Sickle cell disease (56)
Southern California (2104)
Special edition (18)
Spinal muscular atrophy (158)
Sponsored (32)
Startups (3942)
State (2)
Stomach cancer (16)
Supply chain (66)
Tariffs (14)
The Weekly (63)
United States (21541)
Vaccines (761)
Venture capitalists (39)
Webinars (13)
Weight loss (284)
Women's health (33)
Worklife (19)
Date
Today (69)
Last 7 days (679)
Last 30 days (2661)
Last 365 days (34358)
2025 (8527)
2024 (36187)
2023 (41183)
2022 (52535)
2021 (57175)
2020 (56110)
2019 (49596)
2018 (37713)
2017 (34197)
2016 (33481)
2015 (38843)
2014 (29875)
2013 (25479)
2012 (27189)
2011 (27895)
2010 (25386)
Location
Africa (950)
Alabama (54)
Alaska (7)
Arizona (200)
Arkansas (14)
Asia (40919)
Australia (6858)
California (5515)
Canada (1873)
China (492)
Colorado (255)
Connecticut (271)
Delaware (128)
Europe (93581)
Florida (833)
Georgia (206)
Hawaii (1)
Idaho (56)
Illinois (514)
India (26)
Indiana (300)
Iowa (8)
Japan (146)
Kansas (98)
Kentucky (23)
Louisiana (10)
Maine (66)
Maryland (860)
Massachusetts (4253)
Michigan (223)
Minnesota (355)
Mississippi (2)
Missouri (81)
Montana (29)
Nebraska (24)
Nevada (56)
New Hampshire (68)
New Jersey (1626)
New Mexico (26)
New York (1617)
North Carolina (999)
North Dakota (7)
Northern California (2435)
Ohio (197)
Oklahoma (14)
Oregon (35)
Pennsylvania (1217)
Puerto Rico (10)
Rhode Island (25)
South America (1307)
South Carolina (19)
South Dakota (1)
Southern California (2104)
Tennessee (98)
Texas (822)
Utah (163)
Virginia (134)
Washington D.C. (61)
Washington State (551)
West Virginia (3)
Wisconsin (52)
698,143 Results for "fresenius se".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Fresenius Receives FDA Approval for their Denosumab Biosimilars and Secures Global Settlement Agreement
March 27, 2025
·
4 min read
Press Releases
Fresenius Kabi Introduces Calcitonin Salmon Injection, USP Synthetic
February 10, 2025
·
5 min read
Press Releases
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)
March 3, 2025
·
13 min read
Press Releases
Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum
March 13, 2025
·
4 min read
Business
Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024
Evotec SE will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024.
May 15, 2024
·
3 min read
Business
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
The Supervisory Board of Evotec SE has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer, effective 01 July 2024.
April 23, 2024
·
6 min read
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
BioNTech SE held its Annual General Meeting , May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly.
May 17, 2024
·
4 min read
Press Releases
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
December 11, 2024
·
7 min read
FDA
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Fresenius, via its operating company Fresenius Kabi, announced the immediate U.S. availability of Tyenne®, a biosimilar of Actemra®.
April 15, 2024
·
14 min read
Business
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.
April 17, 2024
·
3 min read
1 of 69,815
Next
